203 related articles for article (PubMed ID: 26590014)
1. Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation.
Kim YH; Ahn SJ; Kim YC; Kim KS; Oh IJ; Ban HJ; Chung WK; Nam TK; Yoon MS; Jeong JU; Song JY
Jpn J Clin Oncol; 2016 Feb; 46(2):144-51. PubMed ID: 26590014
[TBL] [Abstract][Full Text] [Related]
2. A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401.
Oh IJ; Kim KS; Kim YC; Ban HJ; Kwon YS; Kim YI; Lim SC; Chung WK; Nam TK; Song JY; Yoon MS; Ahn SJ
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1247-54. PubMed ID: 24091849
[TBL] [Abstract][Full Text] [Related]
3. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
4. [Weekly paclitaxel and carboplatin with concurrent three dimensional conformal radiotherapy for locally advanced non small cell lung cancer].
Wang J; Pang QS; Wang P; Wang J; Wang W
Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):769-72. PubMed ID: 18396691
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105.
Salama JK; Stinchcombe TE; Gu L; Wang X; Morano K; Bogart JA; Crawford JC; Socinski MA; Blackstock AW; Vokes EE;
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e269-74. PubMed ID: 21477940
[TBL] [Abstract][Full Text] [Related]
6. Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer.
Tang C; Lee MS; Gomez D; Levy LB; Zhuang Y; Lu C; Liao Z; Komaki R
Am J Clin Oncol; 2017 Dec; 40(6):625-630. PubMed ID: 26165417
[TBL] [Abstract][Full Text] [Related]
7. Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer.
Divers SG; Spencer SA; Carey D; Busby EM; Hyatt MD; Robert F
J Clin Oncol; 2005 Sep; 23(27):6664-73. PubMed ID: 16170174
[TBL] [Abstract][Full Text] [Related]
8. Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
De Petris L; Lax I; Sirzén F; Friesland S
Med Oncol; 2005; 22(4):375-81. PubMed ID: 16260855
[TBL] [Abstract][Full Text] [Related]
9. Long-term Outcomes of Induction Carboplatin and Gemcitabine Followed by Concurrent Radiotherapy With Low-dose Paclitaxel and Gemcitabine for Stage III Non-small-cell Lung Cancer.
Guilbault C; Garant A; Faria S; Owen S; Ofiara L; Duclos M; Hirsh V; Kopek N
Clin Lung Cancer; 2017 Sep; 18(5):565-571. PubMed ID: 28344046
[TBL] [Abstract][Full Text] [Related]
10. Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer.
Kerner GS; van Dullemen LF; Wiegman EM; Widder J; Blokzijl E; Driever EM; van Putten JW; Liesker JJ; Renkema TE; Pieterman RM; Mertens MJ; Hiltermann TJ; Groen HJ
Radiat Oncol; 2014 Aug; 9():190. PubMed ID: 25174943
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer.
Movsas B; Langer CJ; Ross HJ; Wang L; Jotte RM; Feigenberg S; Xu F; Huang CH; Monberg MJ; Obasaju CK
J Thorac Oncol; 2010 May; 5(5):673-9. PubMed ID: 20354453
[TBL] [Abstract][Full Text] [Related]
12. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
[TBL] [Abstract][Full Text] [Related]
13. Effect analysis of chemoradiotherapy after operation in patients with stage III A non-small cell lung cancer.
Chen S; Cheng YL; Li ST; Ni YJ; Gu B
Asian Pac J Trop Med; 2012 Oct; 5(10):823-7. PubMed ID: 23043924
[TBL] [Abstract][Full Text] [Related]
14. Important prognostic factors for the long-term survival in non-small cell lung cancer patients treated with combination of chemotherapy and conformal radiotherapy.
Crvenkova S; Pesevska M
J BUON; 2015; 20(3):775-81. PubMed ID: 26214630
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer.
Zhang J; Gay HA; Russo S; Parent T; Aljumaily R; Walker PR
Lung Cancer; 2014 Jan; 83(1):67-72. PubMed ID: 24246506
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer.
Lee DH; Han JY; Cho KH; Pyo HR; Kim HY; Yoon SJ; Lee JS
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1037-44. PubMed ID: 16024178
[TBL] [Abstract][Full Text] [Related]
17. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
[TBL] [Abstract][Full Text] [Related]
18. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.
Machtay M; Duan F; Siegel BA; Snyder BS; Gorelick JJ; Reddin JS; Munden R; Johnson DW; Wilf LH; DeNittis A; Sherwin N; Cho KH; Kim SK; Videtic G; Neumann DR; Komaki R; Macapinlac H; Bradley JD; Alavi A
J Clin Oncol; 2013 Oct; 31(30):3823-30. PubMed ID: 24043740
[TBL] [Abstract][Full Text] [Related]
19. Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer.
Liew MS; Sia J; Starmans MH; Tafreshi A; Harris S; Feigen M; White S; Zimet A; Lambin P; Boutros PC; Mitchell P; John T
Cancer Med; 2013 Dec; 2(6):916-24. PubMed ID: 24403265
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401.
Takayama K; Inoue K; Tokunaga S; Matsumoto T; Oshima T; Kawasaki M; Imanaga T; Kuba M; Takeshita M; Harada T; Shioyama Y; Nakanishi Y
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1353-9. PubMed ID: 24166107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]